- Molecular NameHaloperidol
- SynonymNA
- Weight375.871
- Drugbank_IDDB00502
- ACS_NO52-86-8
- Show 2D model
- LogP (experiment)3.36
- LogP (predicted, AB/LogP v2.0)3.62
- pka8.66
- LogD (pH=7, predicted)1.98
- Solubility (experiment)0.014 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.94
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.05
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds6
- TPSA40.54
- StatusFDA approved
- AdministrationN/A
- PharmacologyA typical antipsychotic. It is in the butyrophenone class of antipsychotic medications and has pharmacological effects similar to the phenothiazines.
- Absorption_value100.0
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- Bioavailability60.0
- Protein binding92.0
- Volume of distribution (VD)18 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, about 0.93.
- MetabollsmHaloperidol is also metabolised by reduction of the ketone group to a secondary alcohol (reduced haloperidol).
- Half life18 h
- ExcretionIt is slowly excreted in the urine, about 40% of a dose being eliminated in 5 days with only about 1% of the dose as unchanged drug; about 15% of a dose is excreted in the bile. It is metabolised by oxidative N-dealkylation. Metabolites which have been identified in urine are 4-fluorobenzoylpropionic acid and 4-fluorophenylaceturic acid (the glycine conjugate of 4-fluorophenylacetic acid), both of which are inactive.
- Urinary Excretion1
- Clerance11.8 ml/min/kg
- ToxicityThe minimum lethal dose is probably in excess of 3 g. Toxic effects may appear with blood concentrations greater than about 0.05 mg/L but there is considerable inter-subject variation.
- LD50 (rat)LD50=165 mg/kg
- LD50 (mouse)N/A